Cargando…

Impact of glucose tolerance on the severity of non‐alcoholic steatohepatitis

Aims/Introduction: We investigated the relationship between non‐alcoholic steatohepatitis (NASH) and different stages of fasting plasma glucose (FPG) concentrations, and the association between factors related to glucose tolerance and severity of NASH. Materials and Methods: A total of 147 patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Akinobu, Yoneda, Masato, Fujita, Koji, Tajima, Kazuki, Kikuchi, Kaori, Nakajima, Atsushi, Maeda, Shin, Terauchi, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014908/ https://www.ncbi.nlm.nih.gov/pubmed/24843533 http://dx.doi.org/10.1111/j.2040-1124.2011.00134.x

Ejemplares similares

Modification of a simple clinical scoring system as a diagnostic screening tool for non‐alcoholic steatohepatitis in Japanese patients with non‐alcoholic fatty liver disease
por: Nakamura, Akinobu, et al.
Publicado: (2013)

Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Role of insulin receptor substrate‐1 for diethylnitrosamine plus high‐fat diet‐induced hepatic tumorigenesis in mice
por: Zolzaya, Khadbaatar, et al.
Publicado: (2014)

Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis
por: Ogawa, Yuji, et al.
Publicado: (2013)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
por: Honda, Yasushi, et al.
Publicado: (2017)

AMPK Is Involved in the Regulation of Incretin Receptors Expression in Pancreatic Islets under a Low Glucose Concentration
por: Tajima, Kazuki, et al.
Publicado: (2013)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance
por: Masuda, Kiyomi, et al.
Publicado: (2011)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Proinsulin is sensitive to reflect glucose intolerance
por: Nakamura, Akinobu, et al.
Publicado: (2019)

Effect of long‐term treatment with a small‐molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function
por: Nakamura, Akinobu, et al.
Publicado: (2011)

Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease
por: Nishimiya, Noriko, et al.
Publicado: (2021)

Lessons from Mouse Models of High-Fat Diet-Induced NAFLD
por: Nakamura, Akinobu, et al.
Publicado: (2013)

Present status of clinical deployment of glucokinase activators
por: Nakamura, Akinobu, et al.
Publicado: (2015)

Impaired insulin secretion and related factors in East Asian individuals
por: Nakamura, Akinobu, et al.
Publicado: (2021)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Impact of Glucose Loading on Variations in CD4(+) and CD8(+) T Cells in Japanese Participants with or without Type 2 Diabetes
por: Miya, Aika, et al.
Publicado: (2018)

Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort
por: Imajo, Kento, et al.
Publicado: (2021)

Involvement of Periodontal Disease in the Pathogenesis and Exacerbation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: A Review
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution
por: Nozaki, Yuichi, et al.
Publicado: (2015)

Impact of glucose excursion and mean glucose concentration in oral glucose-tolerance test on oxidative stress among Japanese Americans
por: Nakanishi, Shuhei, et al.
Publicado: (2013)

Relationship between urinary sodium excretion and pioglitazone‐induced edema
por: Nakamura, Akinobu, et al.
Publicado: (2010)

Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Honda, Yasushi, et al.
Publicado: (2020)

Conophylline inhibits non-alcoholic steatohepatitis in mice
por: Nakade, Yukiomi, et al.
Publicado: (2017)

Associations of impaired glucose tolerance and sleep disorders with mortality among the US general population
por: Inoue, Kosuke, et al.
Publicado: (2021)

Differential Effects of Dietary Components on Glucose Intolerance and Non-Alcoholic Steatohepatitis
por: Skat-Rørdam, Josephine, et al.
Publicado: (2021)

Distal gastrectomy for gastric carcinoma in patients with diabetes mellitus: impact of reconstruction type on glucose tolerance
por: Nakamura, Kenichi, et al.
Publicado: (2019)

Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2013)

Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis
por: Kuramoto, Junko, et al.
Publicado: (2022)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Alcohol consumption is associated with an increased risk of erosive esophagitis and Barrett's epithelium in Japanese men
por: Akiyama, Tomoyuki, et al.
Publicado: (2008)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Peroxisome Proliferator-Activated Receptor Gamma Exacerbates Concanavalin A-Induced Liver Injury via Suppressing the Translocation of NF-κB into the Nucleus
por: Ogawa, Yuji, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7rh63f738c78dq47vqprkhaipc